- Home
- GYRE vs PBAM Comparison
GYRE vs PBAM Comparison
Compare GYRE & PBAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GYRE | PBAM |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 606.4M | 490.7M |
| IPO Year | 2004 | 2017 |
Fundamental Metrics
Financial Performance| Metric | GYRE | PBAM |
|---|---|---|
| Price | $6.68 | $86.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | ★ 45.0K | 16.0K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $275,000.00 | N/A |
| Revenue This Year | $19.88 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.44 | $83.50 |
| 52 Week High | $9.42 | $87.00 |
Technical Indicators
Market Signals| Indicator | GYRE | PBAM |
|---|---|---|
| Relative Strength Index (RSI) | 58.90 | 81.94 |
| Support Level | $5.67 | $85.38 |
| Resistance Level | $8.28 | $87.00 |
| Average True Range (ATR) | 0.32 | 0.97 |
| MACD | 0.08 | 0.17 |
| Stochastic Oscillator | 78.83 | 91.43 |
Price Performance
Historical ComparisonAbout GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About PBAM Private Bancorp of America Inc. Common Stock
Private Bancorp of America Inc is a commercial bank chartered by the State of California. It provides comprehensive banking services, including deposit accounts, treasury management services, and lending solutions tailored to high-net-worth individuals, professionals, family offices, closely-held businesses, real estate entrepreneurs, and small to mid-sized businesses. Lending activities include commercial real estate loans, commercial and industrial loans, and government-guaranteed lending programs.